Jenna Armentor
Family · Saint Martinville, LANPI 1952042822
Payments from drug & device makers
Across 134 payments — averaging $17.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$957
- Johnson & Johnson$298
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$269
- Takeda Pharmaceuticals U.S.A., Inc.$93
- QOL Medical, LLC$87
- Ardelyx, Inc.$82
- plus $499 from 13 others
What the payments were for
- Food & beverage$2,03889%
- Education$24811%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 60 | $957 |
| Johnson & Johnson | 13 | $298 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 18 | $269 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $93 |
| QOL Medical, LLC | 4 | $87 |
| Ardelyx, Inc. | 5 | $82 |
| Celltrion USA Inc. | 4 | $82 |
| Intercept Pharmaceuticals, Inc. | 5 | $70 |
| Phathom Pharmaceuticals, Inc. | 4 | $65 |
| Pfizer | 3 | $55 |
| Merck | 2 | $35 |
| Boehringer Ingelheim | 2 | $31 |
| Braintree Laboratories, Inc. | 2 | $31 |
| Lilly USA, LLC | 2 | $30 |
| Gilead | 1 | $26 |
| Sanofi | 1 | $25 |
| Ipsen Biopharmaceuticals, Inc | 1 | $18 |
| Ironwood Pharmaceuticals, Inc | 1 | $16 |
| Bristol Myers Squibb | 1 | $15 |
How this compares
$2,286 in reported general payments places this provider in the 75th percentile of 3,610 family providers in Louisiana.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CreonLipase/Protease/Amylase | 51 | $152,517 |
| LinzessLinaclotide | 160 | $88,363 |
| Dexlansoprazole DrDexlansoprazole | 74 | $13,632 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 161 | $10,025 |
| TrulancePlecanatide | 15 | $7,984 |
| Lubiprostone | 69 | $6,337 |
| ClenpiqSod Picosulf/Mag Ox/Citric Ac | 37 | $6,157 |
| Esomeprazole Magnesium | 229 | $6,076 |
| Famotidine | 545 | $4,717 |
| Pantoprazole Sodium | 450 | $4,065 |
| SuflavePeg 3350/Sod Sulf,chlr/Pot/Mag | 18 | $2,286 |
| Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl | 90 | $1,423 |
| Clarithromycin | 18 | $720 |
| Metoclopramide Hcl | 123 | $647 |
| Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl | 32 | $497 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieCreon, Linzess | $957 | $240,880211 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance | $269 | $7,98415 claims |
| Braintree Laboratories, Inc.Suflave | $31 | $2,28618 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 3,610 family providers in Louisiana.
Other family in Saint Martinville
- Rebecca EzellSlidell$268K
- Erin PierceNew Orleans$261K
- Tavell KindallNew Orleans$194K
- Ashlea HillRuston$169K
- Brittany MillerVille Platte$158K
- Ryanne ClarkeGretna$123K
- Elidia DewittBaton Rouge$108K
- Rebekah GarrardLafayette$105K
- Tiffany RoeShreveport$97K
- Ghenet GhebretatiosBaton Rouge$91K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.